Your browser doesn't support javascript.
loading
[Allogeneic hematopoietic stem cell transplantation using myeloablative conditioning including total body irradiation for pediatric acute lymphoblastic leukemia: a single-center retrospective analysis].
Honda, Mamoru; Arakawa, Yuki; Kawakami, Ryota; Itabashi, Toshikazu; Yanagi, Masato; Sasaki, Koji; Watanabe, Kentaro; Isobe, Kiyotaka; Mori, Makiko; Hanada, Ryoji; Koh, Katsuyoshi.
Afiliação
  • Honda M; Department of Hematology/Oncology, Saitama Children's Medical Center.
  • Arakawa Y; Department of Hematology/Oncology, Saitama Children's Medical Center.
  • Kawakami R; Department of Hematology/Oncology, Saitama Children's Medical Center.
  • Itabashi T; Department of Hematology/Oncology, Saitama Children's Medical Center.
  • Yanagi M; Department of Hematology/Oncology, Saitama Children's Medical Center.
  • Sasaki K; Department of Hematology/Oncology, Saitama Children's Medical Center.
  • Watanabe K; Department of Hematology/Oncology, Saitama Children's Medical Center.
  • Isobe K; Department of Hematology/Oncology, Saitama Children's Medical Center.
  • Mori M; Department of Hematology/Oncology, Saitama Children's Medical Center.
  • Hanada R; Department of Hematology/Oncology, Saitama Children's Medical Center.
  • Koh K; Department of Hematology/Oncology, Saitama Children's Medical Center.
Rinsho Ketsueki ; 59(4): 373-382, 2018.
Article em Ja | MEDLINE | ID: mdl-29743395
This study aimed to investigate the clinical outcomes of hematopoietic stem cell transplantation (HSCT) with total body irradiation-based myeloablative conditioning (TBI-MAC) in pediatric patients with acute lymphoblastic leukemia (ALL). We retrospectively examined patients with ALL who underwent HSCT with TBI-MAC from January 2000 to August 2016 at our institute. We enrolled 67 patients with a median follow-up period of 8 years. The 5-year event-free survival (EFS) and overall survival (OS) were 51.2% and 59.6%, respectively. At the first complete remission, HSCT exhibited significantly superior EFS and OS in our patients than that in patients with other diseases. We encountered 57.9% of patients with at least one late complication. Major late complications were short stature (26.3%) and hypogonadism (18.4%). While late complications were observed in several recipients of HSCT, late complication-related deaths occurred in three patients. The TBI-MAC regimen led to favorable clinical outcomes in pediatric patients with ALL who underwent HSCT. Thus, proper evaluation and management of late complications are mandatory.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Leucemia-Linfoma Linfoblástico de Células Precursoras Idioma: Ja Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Leucemia-Linfoma Linfoblástico de Células Precursoras Idioma: Ja Ano de publicação: 2018 Tipo de documento: Article